Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc.

TRDANYSE / NASDAQHealthcareSmall cap

$4.35-$0.29 (-6.2%)

Last close · Data as of Nov 20, 2026

Market cap
$271.7M
P/E
-1.9x
EV / EBITDA
-1.5x
Revenue
$25.4M
Net margin
-565.5%
ROCE
-44.7%

This period includes a one-day price step on 7 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Entrada Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-12.8%
3M
-42.8%
6M
-28.0%
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 7 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 7 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.29 (-6.2%) from $4.64 to $4.35 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TRDA, bought on each weekday since 2021.

News & filings

What Entrada Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 144 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • This period includes a one-day price step on 7 May 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.

Read moreShow less

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Shares outstanding
38.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$271.7M
P/E
-1.9x
P/B
0.9x
EV / EBITDA
-1.5x
EV / Sales
9.1x
P/S
10.7x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
-621.1%
Net margin
-565.5%
EBITDA margin
-605.0%
ROE
-47.0%
ROCE
-44.7%
ROIC
-46.8%
ROA
-38.1%
Asset turnover
0.07

Growth

Revenue
$25.4M
Revenue growth, 1Y
-87.9%
Net profit growth, 1Y
-319.0%
Free cash flow
-$129.6M

Solvency

Current ratio
12.53
Debt / Equity
0.17
Debt / Assets
0.13
CFO / Net profit
0.89
Cash / Market cap
33.3%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$25.4M
Gross profit$25.4M
Operating expenses$183.3M
Research and development$142.3M
Selling, general and administrative$41.0M
Operating income-$157.9M
Interest and other$15.1M
Pretax income-$142.8M
Tax and other$920.0k
Net income-$143.8M

Revenue and net profit

Revenue fell 87.9% in FY2025; net profit is the dashed line.

Entrada Therapeutics, Inc. revenue and net profit by fiscal year
Entrada Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$94.6M
FY2023$129.0M-$6.7M
FY2024$210.8M$65.6M
FY2025$25.4M-$143.8M

Cash flows

FY2025: -$128.5M from operations, -$129.6M free after investment (dashed).

Entrada Therapeutics, Inc. operating and free cash flow by fiscal year
Entrada Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$93.8M-$96.7M
FY2023$139.8M$134.2M
FY2024-$41.6M-$44.7M
FY2025-$128.5M-$129.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$25.4M-87.9%1Y
EBITDA
-$153.8M-402.9%1Y
Net profit
-$143.8M-319.0%1Y
Cash from operations
-$128.5M
Free cash flow
-$129.6M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$25.4M-$153.8M-$143.8M-$129.6M-47.0%-87.9%-319.0%

Monthly returns

Month-by-month returns of TRDA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$377.4M
Liabilities$71.2M
Equity$306.1M
Paid-in capital$578.6M
Retained earnings-$273.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TRDA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Entrada Therapeutics, Inc. (this company)9.1x

Not shown (no positive earnings and no EV / Sales): Eledon Pharmaceuticals, Inc., Anavex Life Sciences Corp., Nuvectis Pharma, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Entrada Therapeutics, Inc.TRDAthis company$271.7M-1.9x0.9x-47.0%-1.5x
OraSure Technologies, Inc.OSUR$287.1M-4.2x0.8x-20.2%-1.7x
Niagen Bioscience, Inc.NAGE$278.8M16.0x3.6x22.7%13.8x
Quantum-Si incorporatedQSI$278.7M-2.8x1.3x-46.0%-2.8x
Eledon Pharmaceuticals, Inc.ELDN$277.9M-6.1x3.4x-56.3%-3.1x
Anavex Life Sciences Corp.AVXL$261.3M-5.6x2.8x-48.9%—
Akebia Therapeutics, Inc.AKBA$260.3M-48.7x8.0x-16.4%5.9x
Fate Therapeutics, Inc.FATE$257.6M-1.9x1.2x-65.8%-2.1x
Nuvectis Pharma, Inc.NVCT$256.5M-9.7x13.9x-143.6%—
Peer median—-4.9x3.1x-47.5%-1.9x

Year-to-date ROI

TRDA since 1 January, against earlier years.

Historical volatility

TRDA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Entrada Therapeutics, Inc. operating margin by fiscal year
Entrada Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2023-2.4%
FY202422.3%
FY2025-621.2%
LineFY2025
Operating expensesOperating Expense$183.3M
Research and developmentResearch And Development$142.3M
Total expensesTotal Expenses$183.3M
Pretax incomePretax Income-$142.8M

Learn while you research

Academy chapters picked for Entrada Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →